Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy

Journal of the American College of Cardiology

Volumn 58, Issue 24, 2011, Pages 2511-2519

  Van De Veerdonk, Mariëlle C ^a   Kind, Taco ^a   Marcus, J Tim ^a   Mauritz, Gert Jan ^a   Heymans, Martijn W ^a   Bogaard, Harm Jan ^a,b   Boonstra, Anco ^a   Marques, Koen M J ^a   Westerhof, Nico ^a,c   Vonk Noordegraaf, Anton ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

hemodynamics; magnetic resonance imaging; pulmonary arterial hypertension; right ventricular function; survival

Indexed keywords

CALCIUM ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; FEMALE; HEART CATHETERIZATION; HEART DISEASE; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RIGHT VENTRICULAR DYSFUNCTION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

DISEASE PROGRESSION; EXERCISE TEST; FEMALE; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; STROKE VOLUME; SURVIVAL ANALYSIS; VASCULAR RESISTANCE; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 82455203954     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.06.068     Document Type: Article

References (32)

1. V.V. McLaughlin, and M.D. McGoon Pulmonary arterial hypertension Circulation 114 2006 1417 1431 (Pubitemid 44454562)
2. N.F. Voelkel, R.A. Quaife, and L.A. Leinwand Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure Circulation 114 2006 1883 1891 (Pubitemid 44673364)
3. M. Humbert, O. Sitbon, and A. Chaouat Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
4. R.L. Benza, D.P. Miller, and M. Gomberg-Maitland Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
5. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres Survival in patients with primary pulmonary hypertension Results from a national prospective registry Ann Intern Med 115 1991 343 349
6. H.J. Reesink, J.T. Marcus, and I.I. Tulevski Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle J Thorac Cardiovasc Surg 133 2007 58 64 (Pubitemid 46014247)
7. E. Mayer, M. Dahm, and U. Hake Mid-term results of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension Ann Thorac Surg 61 1996 1788 1792 (Pubitemid 26179731)
8. M.K. Pasque, E.P. Trulock, and J.D. Cooper Single lung transplantation for pulmonary hypertension Single institution experience in 34 patients Circulation 92 1995 2252 2258
9. N. Galie, A. Manes, L. Negro, M. Palazzini, M.L. Bacchi-Reggiani, and A. Branzi A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394 403
10. N. Galie, A. Torbicki, and R. Barst Guidelines on diagnosis and treatment of pulmonary arterial hypertension The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur Heart J 25 2004 2243 2278
11. ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
12. W.M. Bradlow, M.L. Hughes, and N.G. Keenan Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size J Magn Reson Imaging 31 2010 117 124
13. S.A. van Wolferen, J.T. Marcus, and A. Boonstra Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension Eur Heart J 28 2007 1250 1257 (Pubitemid 47343830)
14. N. Zafrir, B. Zingerman, and A. Solodky Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome Int J Cardiovasc Imaging 23 2007 209 215 (Pubitemid 46431545)
15. S.M. Kawut, E.M. Horn, and K.K. Berekashvili New predictors of outcome in idiopathic pulmonary arterial hypertension Am J Cardiol 95 2005 199 203 (Pubitemid 40092084)
16. S. Ghio, A. Gavazzi, and C. Campana Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure J Am Coll Cardiol 37 2001 183 188 (Pubitemid 32051736)
17. R.J. Roeleveld, A. Vonk-Noordegraaf, and J.T. Marcus Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension Chest 125 2004 572 579 (Pubitemid 38223638)
18. K.M. Chin, M. Kingman, and J.A. de Lemos Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension Am J Cardiol 101 2008 1669 1672
19. M.R. Wilkins, G.A. Paul, and J.W. Strange Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study Am J Respir Crit Care Med 171 2005 1292 1297 (Pubitemid 40740738)
20. N. Galie, A.L. Hinderliter, and A. Torbicki Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension J Am Coll Cardiol 41 2003 1380 1386 (Pubitemid 36439000)
21. M.M. Hoeper, H. Gall, and H.J. Seyfarth Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Eur Respir J 34 2009 132 137
22. R.L. Benza, B.K. Rayburn, J.A. Tallaj, S.V. Pamboukian, and R.C. Bourge Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan Chest 134 2008 139 145 (Pubitemid 352008775)
23. S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jais, and G. Simonneau Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur Heart J 27 2006 589 595
24. H.A. Ghofrani, F. Rose, and R.T. Schermuly Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J Am Coll Cardiol 42 2003 158 164 (Pubitemid 36760778)
25. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788 (Pubitemid 34925627)
26. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
27. J.W. Lankhaar, N. Westerhof, and T.J. Faes Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension Eur Heart J 29 2008 1688 1695 (Pubitemid 351957537)
28. J.W. Lankhaar, N. Westerhof, and T.J. Faes Quantification of right ventricular afterload in patients with and without pulmonary hypertension Am J Physiol Heart Circ Physiol 291 2006 H1731 H1737 (Pubitemid 44497678)
29. N. Saouti, N. Westerhof, and F. Helderman Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure Am J Respir Crit Care Med 182 2010 1315 1320
30. S.M. Kawut, N. Al-Naamani, and C. Agerstrand Determinants of right ventricular ejection fraction in pulmonary arterial hypertension Chest 135 2009 752 759
31. A.D. Sniderman, and D.H. Fitchett Vasodilators and pulmonary arterial hypertension: the paradox of therapeutic success and clinical failure Int J Cardiol 20 1988 173 181
32. S. Suissa Immortal time bias in pharmaco-epidemiology Am J Epidemiol 167 2008 492 499